Further testing of a new cancer drug has shown it significantly restricts tumour growth when combined with other, widely-available, chemotherapeutic drugs.
The drug, DMXAA was discovered by a team at the Auckland Cancer Society Research Centre, and is now under development by UK-based Antisoma.
It selectively restricts blood vessels feeding solid tumours. The recent studies showed DMXAA additionally impeded tumour growth when administered with other chemotherapy drugs. Further clinical studies are planned.